Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Marina Moreira Costa Zorzetto"'
Autor:
Cristiano de Pádua Souza, Ana Suellen Barroso Carneiro, Ana Cecília de Oliveira Lessa, Domício Carvalho Lacerda, Carlos Eduardo Paiva, Marina Moreira Costa Zorzetto, Ana Julia Aguiar de Freitas, Iara Viana Vidigal Santana, Marco Antonio de Oliveira, Edenir Inêz Palmero, Márcia Maria Chiquitelli Marques, Tomás Reinert
Background Neoadjuvant chemotherapy (NACT) is the mainstay of treatment of stages II and III triple-negative breast cancer (TNBC). There is interest in the addition of carboplatin to NACT, especially in TNBC patients with germline BRCA mutations or o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89df95af7e631a7e19aa2685f1b050db
https://doi.org/10.21203/rs.3.rs-2874299/v1
https://doi.org/10.21203/rs.3.rs-2874299/v1
Autor:
Hirotaka Iwase, Petr V. Krivorotko, Marina Moreira Costa Zorzetto, Rubi K. Li, Rajesh Aggarwal, Reginald Ewesuedo, Sachin Hingmire, Ray Li, Mark D. Pegram, Keun Seok Lee, Amy Freyman, Elizabeth Tan-Chiu, Igor Bondarenko, Charles Zacharchuk, Joanna Pikiel, Alicia M. Vana, Donghua Yin
Publikováno v:
British Journal of Cancer
Background This randomised, double-blind study compared PF-05280014 (a trastuzumab biosimilar) with reference trastuzumab (Herceptin®) sourced from the European Union (trastuzumab-EU), when each was given with paclitaxel as first-line treatment for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56ee48282e4e93330200e912cfb4d59c
https://doi.org/10.1038/s41416-018-0340-2
https://doi.org/10.1038/s41416-018-0340-2
Autor:
Alison Wagner Azevedo Barroso, Daniel D’Almeida Preto, Ana Lima Veneziani, Maria Augusta Zaffari Safro, Maria Budib, André Octavio Nicolau Sanches, Gustavo Sanches Faria Pinto, Alan Felipe Bello Secco, Marina Moreira Costa Zorzetto, Carlos Eduardo Paiva, Cristiano de Pádua Souza, Domício Carvalho Lacerda, Alessandra Caroline Moretto Carbinatto, Georgia Kons
Publikováno v:
Journal of Clinical Oncology. 37:e12105-e12105
e12105 Background: The best sequence of anthracyclines and taxanes in the neoadjuvant chemotherapy of HER2-negative breast cancer is still unknown. The aims of this study were to assess the impact of the sequence order in the pathological complete re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7a97c9f522de39e38a0f4d17423e561
https://doi.org/10.1200/jco.2019.37.15_suppl.e12105
https://doi.org/10.1200/jco.2019.37.15_suppl.e12105